On behalf of Dr. Adam Morgenthau, a pulmonologist at the Icahn School of Medicine at Mount Sinai whose work focuses on the development of new treatments for sarcoidosis, FSR is asking for your assistance on a research project. Dr. Morgenthau and his team are pioneering a way to engage sarcoidosis patients, as well as advocates and caregivers, in the design of clinical trials to ensure that they are asking the right questions in the right way. Based on promising previous studies, Dr. Morgenthau is asking patients and their advocates to provide input on how to design a better clinical trial that tests Kiacta, a non-steroid, orally administered compound, in sarcoidosis. To accomplish this, he has partnered with Transparency Life Sciences (TLS) to crowdsource the design of the trial using TLSs Protocol Builder tool, which allows patients and researchers to actively influence certain aspects, such as steroid reduction and the role of remote technology. Please click here to begin. You may enter your email address to sign up as a user of TLS’s website, or opt to complete the Protocol Builder anonymously by clicking “Guest.” Please help us incorporate the patients voice into the trial development process. We estimate that 15 minutes of your time will be needed. In addition, if it is appropriate, please share this opportunity with your local sarcoidosis organizations. You may contact Dr. Morgenthau or FSR to answer any comments or questions. Thank you for assisting our efforts to significantly improve the clinical trial process and advance new therapeutic options for sarcoidosis. Again, please help out with your input! Click below to be directed to the TLS website. transparencyls/kiacta-sarcoidosis Thank you! Sincerely, The FSR Team on behalf of Adam S Morgenthau, MD Assistant Professor of Medicine Director of Sarcoidosis Clinic Icahn School of Medicine at Mount Sinai Kiacta in Sarcoidosis | TLS Patients are being asked about their willingness to enroll in a clinical trial for Kiacta in order to estimate participation and/or dropout rates for the trial. transparencyls
Posted on: Fri, 03 Oct 2014 23:35:53 +0000
Trending Topics
Recently Viewed Topics
© 2015